New <i>RAS</i>-Mutant Pancreatic Adenocarcinoma With Combined BRAF and MEK Inhibition for Metastatic Melanoma

Matteo S. Carlino; Vu Kwan; David K. Miller; Catherine A.B. Saunders; Desmond Yip; Adnan Nagrial; Jeanne Tomlinson; Sean M. Grimmond; Richard A Scolyer; Richard Kefford; Andrew V. Biankin; Georgina V. Long

doi:10.1200/jco.2013.51.5783

Discussion(0)

No comments yet. Be the first to comment.

Related publications

Article2016

Resistance to combination BRAF and MEK inhibition in metastatic melanoma: Where to next?

Sarah J. Welsh, Helen Rizos, Richard A Scolyer, Georgina V. Long

Article2012

Distinguishing Clinicopathologic Features of Patients with V600E and V600K <i>BRAF</i> -Mutant Metastatic Melanoma

Alexander M. Menzies, Lauren E. Haydu, Lydia Visintin, Matteo S. Carlino, Julie R. Howle, John F. Thompson, Richard Kefford, Richard A Scolyer, Georgina V. Long

Article2019

The survivorship experience for patients with metastatic melanoma on immune checkpoint and BRAF-MEK inhibitors

Julia Lai‐Kwon, Chloe Khoo, Serigne Lo, Donna Milne, Mustafa Abdi Mohamed, Jeanette Raleigh, Kortnye Smith, Karolina Lisy, Shahneen Sandhu, Michael Jefford

Article2015

Clinicopathologic features associated with efficacy and long‐term survival in metastatic melanoma patients treated with <scp>BRAF</scp> or combined <scp>BRAF</scp> and MEK inhibitors

Alexander M. Menzies, James S. Wilmott, Martin Drummond, Serigne Lo, Megan Lyle, Matthew Chan, John F. Thompson, Alex Guminski, Matteo S. Carlino, Richard A Scolyer, Richard Kefford, Georgina V. Long

Article2014

Eruptive naevi in a patient treated with LGX818 for BRAF mutant metastatic melanoma

Rachael Anforth, Giuliana Carlos, Richard A Scolyer, Shaun Chou, Pablo Fernández‐Peñas